75A50126F61013↗
Seqirus Inc received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $450.1K obligated so far for drugs and biologicals. It runs to 2027-05-08.
Key facts · data as of Oct 26, 2026
- Recipient
- Seqirus Inc
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Obligated to date
- $450.1K
- Potential value
- $450.1K
- Ends
- 2027-05-08
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 26, 2026.
Cite this page: SpendQuery, Award 75A50126F61013, data as of Oct 26, 2026, https://spendquery.com/award?id=CONT_AWD_75A50126F61013_7505_75A50122D00004_7505
Seqirus Inc: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys · The follow-on: recompete brief
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN
Up for re-bid: ends 2027-05-08. Recompete brief →
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Biological Product (Except Diagnostic) Manufacturing (NAICS 325414)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Competition
- Full and open competition
- Pricing
- Firm fixed price
- How it was bought
- Single-award IDIQ · under 75A50122D00004
- Where the work is
- Wake, NC · district NC-13
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
2 actions since 2026-04-03. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-24 | P00001 | Administrative change | $0 | TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN |
| 2026-04-03 | 0 | $450.1K | TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-26). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗